Total amount: € 0,00
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index
Fracchioli S., Katsaros D., Maggiora P., Di Renzo M. F., Massobrio M.
Background. Epithelial ovarian cancer is the most lethal gynecologic neoplasia. Up to date, little is known about its biology, and this makes even more difficult the definition of new therapies and the finding of early diagnostic methods. In this study, the expression of two oncogenes, Ron and Met, whose role in cancer progression has already been shown, and the possible clinical implication of their presence in the neoplastic tissue have been evaluated.
Methods. Forty-eight ovarian cancer specimens, 5 borderline lesions, 4 benign ovarian tumors and 2 normal ovaries were analyzed; from frozen tissue, Rna was extracted and cDna obtained by a RT-PCR (Retrotrascriptase-Polymerase Chain Reaction). Finally, the cDna was assayed for the presence of the Ron and the Met gene by another PCR. The results were correlated with clinicopathological parameters, and patient survival.
Results. Ron expression was shown in 56% of malignant lesions, and in 60% of borderline ones, while Met expression was detected in 54 and 60%, respectively. No statistically significant correlation was found between Ron and Met expression and clinicopathological features, such as histotype, grading, staging, residual tumor after debulking surgery, and response to chemotherapy, while a strong correlation (p=0.001) was observed between overexpression of one of the oncogenes and the concomitant expression of the other.
Conclusions. Even if residual tumor after debulking surgery was the most relevant prognostic factor, this study showed new data about the concomitant expression of Ron and Met oncogenes, which may suggest their cooperative role in ovarian cancer progression.